Intercorrelation of Expression of CD56, CD117, CD33, CD20 Antigens with Survival Rates in Patients with Multiple Myeloma in Gomel Region in Belarus
The detection of immunophenotype of plasma cells is very important for diagnosis of multiple myeloma. Mechanism of appearing of different antigens on the surface of malignant plasma cells and their correlation with overall survival isn't sufficiently studied.
Publication date: Available online 21 October 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Courtney D. Dinardo, Eytan M. Stein
The presence of recurrent genetic mutations in the myeloblasts of patients with acute myeloid leukemia (AML) are prognostic and incorporated into risk stratification systems of both the National Comprehensive Cancer Network and European Leukemia Network.1 In patients with FLT3-internal tandem duplications (FLT3-ITD) or tyrosine kinase domain mutations (TKD) small molecule inhibitors of the resultant mutant proteins in combination with cytotoxic chemotherapy can improve overall survival in newly diagnosed AML patients with a FLT3 mutation.
Publication date: Available online 17 October 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): S.D. Smith, S. Gandhy, A.K. Gopal, P. Reddy, M. Shadman, B.G. Till, R.C. Lynch, S. Kanan, A. Cowan, L. Low, B.T. Hill
We report a relapsed and refractory Multiple Myeloma (RRMM) and AL Amyloidosis patient responding to elotuzumab/lenalidomide/dexamethasone (ERD). A 51-year-old woman presented with a right mandibular mass with positive Congo-red staining, clonal kappa free-light chains (κFLC) and plasma cell proliferation. Workup was consistent with κFLC amyloidosis and MM with nephrotic range proteinuria. After progression on several lines of therapy, she has near complete reversal of proteinuria while being maintained on ERD. This regimen should be tested in patients with AL Amyloidosis.
Intensive first-line treatment for mantle cell lymphoma (MCL), incorporating rituximab and cytarabine followed by autologous stem cell transplantation (ASCT) consolidation for responding patients, affords high response rates and a progression-free survival exceeding 5 years. 1-3 Nonetheless, MCL remains incurable, and high-risk subsets defined by the Mantle Cell International Prognostic Index (MIPI4, 5) do not achieve the same benefit from intensified therapies.2, 6, 7 The Nordic regimen employing intensified rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (maxi-RCHOP) alternating with rituximab and c...
Publication date: Available online 13 October 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): AnnaLynn M. Williams, Andrea Baran, Carla Casulo, Patrick Reagan, Jonathan W. Friedberg, Margaret Helber, Jeremiah Moore, Elizabeth Baloga, Clive S. Zent, Paul M. BarrAbstractBackgroundAs oral targeted agents, such as ibrutinib, become more widely used understanding the impact of suboptimal dosing on overall and progression-free survival outside of clinical trials is imperative.MethodsData on ibrutinib discontinuation, dose reductions and treatment interruptions were collected on 170 non-Hodgkin lymphoma (NHL) and chr...
ConclusionBexarotene monotherapy is well-tolerated and has encouraging activity in PTCL that warrants further investigation. This agent should be considered for further prospective trials in this setting.
Publication date: Available online 13 October 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Ryan B. Sinit, Kathleen L. Horan, Russell K. Dorer, David M. AboulafiaAbstractIn 2016, the World Health Organization provisionally classified Epstein-Barr virus (EBV)-positive mucocutaneous ulcer (EBVMCU) as a lymphoid neoplasm under the subcategory of mature B-cell neoplasms. EBVMCU is manifested as a well-circumscribed ulcer, typically unifocal, and of the oropharynx, gastrointestinal tract, or skin. Immunohistochemical studies of these ulcers reveal monoclonal B-immunoblasts staining positively for CD20, CD30, EBER...
Publication date: Available online 13 October 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Kristine A. Frerichs, Patricia W.C. Bosman, Inger S. Nijhof, S. Zweegman, Niels W.C.J. van de Donk
Conclusionsand Relevance: The combination of rituximab and bendamustine warrants further investigation in the treatment of HS, especially those originating from prior follicular lymphoma. Modern immunohistochemical and molecular profiling techniques are beginning to reveal heterogeneity amongst HS tumors and potentially therapeutic targets.